Shilpa Medicare receives EIR for Andhra Pradesh unit

This R&D site has undergone an inspection by the USFDA during 11 Feb 2019 to 13 Feb 2019, wherein the company has been issued a Form 483 with 1 (one) observation.

Apr 21, 2019 02:04 IST India Infoline News Service

Shilpa Medicare
Shilpa Medicare, in its filing to the exchanges, informed that the company’s Pharmaceutical Research & Development Unit situated at Modavalasa, Vizianagaram of Andhra Pradesh region has received USFDA Establishment Inspection Report (EIR) with intimation of closure of inspection on April 8, 2019.

This R&D site has undergone an inspection by the USFDA during 11 Feb 2019 to 13 Feb 2019, wherein a Form 483 was issued with 1 (one) observation, the company said in a press note on Saturday.

"Based on our responses and follow up actions, the USFDA has determined the inspection classification of this facility as Voluntary Action Initiated (VAI)," the company added.

Shilpa Medicare Ltd's share price ended at Rs398.70, up by Rs22.5 or 5.98%, from its previous close of Rs376.20 on the BSE.
The scrip opened at Rs375.20 and touched a high and low of Rs414.75 and Rs360.90, respectively. A total of, 1,64,222 (NSE+BSE) shares have traded on the counter. The current market cap of the company is Rs3,250.48cr.

Related Story